Postmarketing surveillance does not catch all adverse eventsBMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7030.577 (Published 02 March 1996) Cite this as: BMJ 1996;312:577
- Paul O'Brien
- Session clinical medical officer Raymede Clinic, London W10 5SH
EDITOR,—H B M Reijnen and W J Atsma, of Organon Pharmaceuticals, use data from the company's product surveillance database to show that the risk of venous thromboembolism with the pills Marvelon and Mercilon, both of which contain desogestrel, is highest in the first few months of use and falls dramatically thereafter.1 The World Health Organisation's …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial